The discovery of TAAR1-mediated modulation of dopaminergic neurotransmission led to the investigation of TAAR1 agonists as potential therapeutics for various psychiatric disorders including schizophrenia and substance use disorders. Here, TAAR1 is linked to schizophrenia.